With many reports about this year’s influenza (flu) vaccine ineffectiveness, a new study shows it is more effective than thought, especially among children.
A Phase III, placebo-controlled study demonstrated both low-dose and high-dose therapy with a licensed, self-administered subcutaneous immune globulin product was efficacious and well-tolerated as maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy.
Researchers at Columbia University in New York have found children born to mothers who experience fever, especially multiple fevers, during the second trimester of pregnancy are at increased risk for developing autism spectrum disorder (ASD).
Alex Michael Azar II was confirmed the 24th Secretary of Health and Human Services.
The Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation has launched a new voluntary bundled payment model called Bundled Payments for Care Improvement Advanced.
Abilify MyCite (aripiprazole tablets with sensor; Otsuka Pharmaceutical), the first digital ingestion tracking system, has been approved by the U.S. Food and Drug Administration.
CSL Behring noted the potential for fading print with more effect on the expiration dating on the patient tear-off portion of the vial label.
Researchers have found antibiotics can be counterproductive and weaken the immune system’s ability to fight off bacteria.
A nationwide epidemiological study showed cancer patients who continuously used disulfiram (Antabuse), a drug prescribed to alcoholics to prevent them from drinking, have a lower risk of death from cancer compared to those who stopped using the drug once diagnosed.
The Centers for Medicare and Medicaid Services has proposed a 1.84 percent increase in 2019 Medicare payments to health insurers that manage Medicare Advantage insurance plans for more than 20 million elderly and disabled people.
A Phase III study involving 109 male participants with hemophilia A and inhibitors showed that once-weekly subcutaneous prophylactic administration of an investigational bispecific humanized monoclonal antibody (emicizumab; ACE910) was associated with a significantly lower rate of bleeding events than no prophylaxis.
The U.S. Department of Health and Human Services has proposed 2018 updates to the Medicare hospital outpatient prospective payment system to decrease Medicare Part B payments to hospitals for 340B drugs by almost 30 percent.
